22 March 2018:
Stallergenes Greer has notified ASCIA of a temporary shortage in the supply of the subcutaneous (SCIT) injectable allergen immunotherapy products. The supply of Stallergenes Greer sublingual allergen immunotherapy (SLIT) products is not impacted. Despite this temporary supply shortage from their Antony manufacturing site in France, Stallergenes Greer has existing local stock in Australia and New Zealand. This should enable the continued supply of the full range of their SCIT and SLIT products, with the exception of ALUSTAL 5 grass mix (initial 3 vials).
Patients who are currently receiving (or are being considered) for treatment with Stallergenes Greer SCIT products should speak with their doctor about the potential impact of this temporary supply shortage on their management.
Stallergenes Greer is continuing to upgrade its manufacturing facility and processes at their Antony site in France. Significant improvements supported by substantial investments have already been implemented proactively over the past few months to deliver products that meet the highest quality standards. However, the improvements they are now undertaking will be on a larger scale and will take more time than originally anticipated, resulting in longer manufacturing lead times and temporary shortages.
Stallergenes Greer regrets the impact of this transition phase at their manufacturing site, which is focused on ensuring the continued availability of quality allergen immunotherapy products. All Stallergenes Greer teams are working to make these products available again. Further updates will be provided as soon as more information is available.